BREAKING: Trump Mulls 'Winding Down' Iran War; Stocks Jump Late While investors were spooked by oil-shock prospects, a few stocks continued to hover near new highs. They were also near their latest buy points in Friday's stock market. Two are biotech names. Stock Market: Two Biotech Stocks Hover Near Highs | Investor's Business Daily United Therapeutics (UTHR) jumped to an all-time high of 548.12 on March 10 and has pulled back to a buy zone above a 519.99 entry. United Therapeutics develops treatments for ...

Core Viewpoint - Ligand Pharmaceuticals' stock has experienced a significant decline, dropping 7.8% to $204.04, which places it below its buy point of $212.49, amidst a broader market sell-off despite a positive report from BofA Securities [1]. Group 1 - Ligand Pharmaceuticals' shares fell into a sell zone after a breakout earlier in the week [1]. - The stock's decline occurred even with an upbeat report from BofA Securities, indicating potential underlying issues in the biotech sector [1]. - At one point, Ligand's stock experienced a notable drop, highlighting volatility in the biotech market [1].

Core Viewpoint - Bank of America initiated coverage on Ligand Pharmaceuticals, highlighting the company's unique royalty model and potential for significant upside [1] Ligand's Differentiated Model - Ligand Pharmaceuticals operates as a biopharmaceutical royalty aggregator, providing financing to biopharma developers while licensing its portfolio technologies [2] - The company is supported by experienced management and a proven investment team, positioning it to achieve ambitious revenue and earnings growth targets [2] - Ligand offers investors exposure to biopharma growth opportunities with a comparatively lower risk profile [2] Revenue and Earnings Performance - Ligand's current portfolio includes 12 major commercial-stage assets that generate the majority of its royalty revenues, expected to support profit and loss in the near to mid-term [3] - Analyst Jason Zemansky noted that Ligand has over 100 programs that could provide additional revenues and access to over $1 billion in deployable capital [3] - The company reported fourth-quarter adjusted earnings of $2.02 per share, exceeding the consensus estimate of $1.56, with sales of $59.7 million, surpassing the Wall Street estimate of $55.6 million [4] - Ligand reaffirmed its fiscal 2026 adjusted earnings guidance of $8.00-$9.00 per share, compared to the consensus of $8.29, and maintained sales guidance between $245 million and $285 million, against a consensus of $265.7 million [4] Valuation and Growth Potential - Bank of America stated that Ligand is well-positioned for future success, with higher margins than traditional biopharma firms due to its lack of extensive infrastructure for drug development [5] - Ligand's 5-year growth rates are notable, with expected top- and bottom-line CAGRs of +5% and +12%, respectively, compared to large-cap peers in the pharma and biotech sectors [6] - Ligand's stock increased by 4.30% to $221.42 as of the last check on Wednesday [6]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Insights - Ligand Pharmaceuticals has experienced a significant stock breakout, surpassing multiple buy points and achieving a closing price of $212.29, reflecting a 2% increase [1] - The company operates as an investment entity in the biotech sector, managing over 100 partnered commercial and development-stage programs, which generate royalties from successful drug sales [1] - Following a strong fourth-quarter report, Ligand's royalty revenue is projected to increase by 50% at the midpoint of its guidance [1] Company Performance - Ligand's stock has achieved a strong IBD Composite Rating of 96, ranking it in the top 4% of all stocks based on fundamental and technical measures [1] - The Relative Strength Rating stands at 92, indicating that Ligand's performance over the past 12 months is in the leading 8% of all stocks [1] - The stock's relative strength line is at a record high, showcasing its outperformance compared to the S&P 500 [1] Key Partnerships and Products - Major products include Filspari, partnered with Travere Therapeutics, which generated $9.3 million in royalties, and Ohtuvayre, partnered with Merck, which achieved $196 million in fourth-quarter sales, a 45% sequential increase [1] - Filspari is aimed at treating primary IgA nephropathy and has potential for additional sales in treating focal segmental glomerulosclerosis, with peak sales estimated at $1 billion [1] - Ohtuvayre is approaching blockbuster status, with total sales for 2026 projected to reach $1 billion [1] Oncology Pipeline - Ligand has a diverse oncology pipeline, including partnerships for drugs like Qarziba for neuroblastoma and a drug in collaboration with Leona Bio for breast cancer and osteoporosis [1] - The company is also working with Agenus on a colorectal cancer drug, with royalties ranging from 2.6% to 10% depending on the product [1] - Oppenheimer analyst raised the price target for Ligand stock to $277, reflecting confidence in the company's growth potential [1]

Revenue and Financial Performance - A significant portion of the company's royalty revenue is based on sales from collaboration partners, including Amgen and Merck, with potential revenue from products like Kyprolis and Qarziba being critical for future earnings [142]. - Revenues from sales of Captisol material to collaboration partners represent approximately 50% of the company's royalty revenues, indicating a heavy reliance on this product for financial performance [147]. - Future revenue from royalties on Captisol partnered products may decrease if partners terminate agreements or fail to obtain regulatory approvals, impacting financial results [154]. - The company maintains inventory of Captisol with a five-year shelf life, but supply chain interruptions could adversely affect operations and revenue [151]. - The company relies on partners' sales reports to estimate royalty revenues, which may be subject to revision if partners report incorrect sales or delay earnings releases [263]. - The company may face significant charges to earnings related to acquisitions, including fees for advisors and closure costs associated with integration [257]. - The Inflation Reduction Act of 2022 imposes a 15% minimum tax on book income for certain large corporations, which could adversely affect the company's financial condition [264]. - The company continues to have exposure to risks related to its approximately 50% equity ownership in Pelthos, which could impact financial results [259]. - Changes in financial accounting standards, such as ASC 606, could adversely impact the company's results of operations [262]. Regulatory and Compliance Risks - The company faces risks related to regulatory compliance, which could lead to interruptions in manufacturing and distribution of biopharmaceutical products [152]. - The regulatory approval process for product candidates is lengthy and unpredictable, with a small percentage successfully completing FDA approval [237]. - The company may need to conduct additional clinical trials or studies as required by regulatory authorities, which can delay commercialization [239]. - The company faces ongoing regulatory obligations post-approval, which may result in significant additional expenses [240]. - Compliance with evolving AI regulations may impose operational and financial burdens on the company [236]. - The FDA's ability to review and approve new products may be hindered by changes in government funding and personnel, potentially delaying product development and commercialization [246]. - A reduction in FDA funding or workforce could significantly impact the timely review and processing of regulatory submissions, adversely affecting business operations [248]. - Disruptions at the FDA, including government shutdowns, could lead to delays in the review and approval of new drugs, impacting milestone revenues and overall business operations [249]. Intellectual Property Risks - Intellectual property risks, including potential patent expirations and competition, could adversely affect the company's ability to generate revenue from its products [143]. - The success of the company depends on obtaining and maintaining patents and other intellectual property rights, which involves complex legal and technical questions [180]. - Several third parties have challenged patents covering the company's partner's branded products, which could result in the invalidation of some patent claims [183]. - The company may incur significant costs and expenses related to defending or indemnifying third parties in infringement claims, which could adversely affect its financial condition [191]. - The company relies on trade secrets and know-how to maintain its competitive position, but breaches of confidentiality agreements may occur [189]. - The company may not be able to obtain necessary licenses for third-party intellectual property, which could impede its ability to develop or commercialize new technologies [196]. - The company typically does not control the enforcement of patent rights related to products generating royalties, relying on partners for prosecution and maintenance [202]. - Changes in patent laws could increase uncertainties and costs surrounding patent applications and enforcement, impacting the company's ability to protect its inventions [207]. Market and Competitive Risks - The royalty market may not grow at the same rate as in the past, potentially limiting opportunities for acquiring new royalties and impacting growth strategies [146]. - New products and technologies from competitors may render existing product candidates obsolete, impacting potential revenue from milestones and royalties [167]. - Market acceptance and sales of products depend significantly on coverage and reimbursement from third-party payors, with significant uncertainty regarding reimbursement status [217]. - The Affordable Care Act (ACA) has faced judicial and congressional challenges since its enactment in 2010, impacting the pharmaceutical industry [218]. - The implementation of healthcare reform measures may lead to more rigorous coverage criteria and downward pressure on drug prices, affecting revenue generation [223]. Operational and Supply Chain Risks - The company relies on a sole supplier for Captisol, and any supply chain disruptions could significantly impair operating results and stock market performance [149]. - The company relies on third-party manufacturers for Captisol supply, which could be disrupted by natural or man-made disasters, impacting revenue generation [274]. - Cybersecurity incidents have occurred in the past, and the company expects to face future incidents that could disrupt operations and lead to financial losses [278]. - The company’s operations and financial results could be adversely affected by future pandemics or public health epidemics, impacting business activities and supply chains [303]. Financial and Debt Management - The company must maintain a minimum consolidated EBITDA of $55 million for the trailing four-quarter period ending September 30, 2025, as per the amended Credit Agreement [279]. - The company’s ability to generate cash flow from operations is critical for servicing its indebtedness and funding liquidity needs, which may be affected by various external factors [280]. - The Credit Agreement requires the company to maintain a leverage ratio of no greater than 2.50 to 1.00, increasing to 3.00 to 1.00 for a fiscal quarter following a material acquisition [281]. - The company may face material adverse effects on its business if it breaches covenants in the Credit Agreement, which could lead to an event of default [283]. - The company uses debt to finance capital deployment, which increases the risk of loss if acquired royalties do not generate sufficient income [284]. - The company’s ability to satisfy debt obligations depends on future performance, which is subject to various uncontrollable factors [285]. Investment and Market Risks - The company’s investments are subject to market and credit risks, which could be exacerbated during periods of financial volatility [290]. - The stock price of the company has been volatile, influenced by various factors including clinical trial results and regulatory developments [301]. - The company is exposed to foreign currency risk due to transactions denominated in currencies other than the functional currency, which could lead to substantial gains or losses [386]. - The company does not currently hedge its exposure to foreign currency fluctuations, despite payments to suppliers being adjusted based on foreign currency risk sharing [387]. - The company has not incurred significant losses related to royalty assets or available-for-sale debt securities, but faces risks if counterparties experience financial difficulties [385].

Financial Performance - Ligand Pharmaceuticals reported total GAAP revenue of $268 million for 2025, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [15][16] - Full-year royalty revenue grew to $161 million, an increase of 48% year-over-year, driven by products such as FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [15][16] - Adjusted EPS increased to $8.13, up 42% year-over-year, indicating strong operating leverage and higher royalty contributions [15][16] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [16][17] - Ohtuvayre reported net sales of $178 million in Q4, with full-year sales of $506 million, marking a strong launch in COPD history [17][34] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [17][18] Market Performance - Ligand's royalty portfolio is expected to see a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by contributions across the entire portfolio [12][13] - The company anticipates significant commercial opportunities in Japan for FILSPARI, with a sizable market for IgAN [71] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a systematic portfolio management strategy to drive value across partnerships [9][10][22] - The demand for royalty financing has doubled over the last five years, positioning Ligand favorably within the biopharmaceutical royalty financing sector [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong trial results for QTORIN rapamycin and the successful partnership with Leona Bio for lasofoxifene [36] - The company is optimistic about the upcoming year, expecting multiple catalysts from its late-stage development pipeline [36][31] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [20] - The company reaffirmed its 2026 financial guidance, expecting adjusted EPS of approximately $8-$9 per share and royalty revenue of $200 million-$225 million [20][21] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and TZIELD, with robust updates expected in the coming quarters [39][40] Question: Update on monetizing older assets in the portfolio - Management confirmed active engagement in 5 to 10 opportunities for older assets, with potential announcements expected by year-end [43][44] Question: Larger opportunity for TZIELD and peak sales size - Management acknowledged TZIELD's low royalty but emphasized its potential blockbuster status, particularly with the upcoming Stage 3 indication [48][50] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS contribution to 2026 guidance is modest, with a risk-adjusted estimate of $4 million [53][55] Question: Changes in selection criteria for potential partnerships - Management noted that as the portfolio value grows, the average deal size will increase, focusing on high clinical value assets [58][59]

Financial Data and Key Metrics Changes - Full-year adjusted EPS exceeded original 2025 guidance by more than 30%, with a 42% increase year-over-year [6][7] - Total GAAP revenue for 2025 was $268 million, up from $167 million in 2024, with core revenue reflecting a 43% year-over-year growth at $240 million [15][16] - Royalty revenue grew to $161 million, an increase of 48% year-over-year, driven by products like FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [15][16] Business Line Data and Key Metrics Changes - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total annual sales of $322 million [16][17] - Ohtuvayre reported U.S. net sales of $506 million for the full year 2025, with Q4 sales just under $200 million [17] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [17] Market Data and Key Metrics Changes - The royalty funding market has doubled over the last five years, indicating a growing demand for royalty capital [10][11] - Ligand expects a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by contributions across the entire portfolio [12][13] Company Strategy and Development Direction - Ligand is focused on disciplined investments to create new, clinically differentiated product royalty streams and enhance long-term shareholder value [8][9] - The company launched a systematic portfolio management strategy to proactively communicate with partners and identify new investment opportunities [22][23] - Ligand aims to expand its business development efforts and deepen its pipeline, with a strong capital base to support growth initiatives [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the royalty portfolio and disciplined capital deployment approach, positioning the company for sustained long-term growth [12][13] - The company anticipates significant commercial upside from products like FILSPARI and Ohtuvayre, with ongoing efforts to engage with regulatory bodies for approvals [34][35] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [20] - The company is optimistic about the potential of lasofoxifene and QTORIN rapamycin, with significant market opportunities projected [24][29] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and TZIELD, with robust updates expected in the coming quarters [39][40] Question: Update on monetizing older assets in the portfolio - Management confirmed active engagement in 5 to 10 opportunities for older assets, with potential announcements expected by year-end [43][44] Question: Larger opportunity for TZIELD and peak sales size - Management acknowledged TZIELD's low royalty but emphasized its potential blockbuster status, particularly with the upcoming Stage 3 indication [48][49] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS contribution to 2026 guidance is modest, with a risk-adjusted estimate of $4 million [53][55] Question: Changes in selection criteria for potential partnerships - Management noted that as the portfolio value grows, the average deal size sought will increase, focusing on high clinical value assets [58][59] Question: Market size opportunity for FILSPARI in IgAN and FSGS - Management estimated consensus market size for both indications at around $1 billion, with potential royalties of approximately $90 million for each [70][71]

Financial Performance - In 2025, Ligand Pharmaceuticals achieved total GAAP revenue of $268 million, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [12][13] - Full-year adjusted EPS increased to $8.13, a 42% rise year-over-year, driven by strong operating leverage and higher royalty contributions [13][10] - Royalty revenue grew to $161 million, marking a 48% increase year-over-year, primarily from FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [12][5] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [13][14] - Ohtuvayre reported U.S. net sales of $506 million for the full year 2025, with Q4 sales of nearly $200 million [14] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [15] Market Data - The royalty financing market has doubled over the last five years, indicating a growing demand for royalty capital [9] - Ligand expects a compound annual growth rate of 23% in royalty receipts from 2025 through 2030, driven by contributions across its portfolio [10] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a strong emphasis on proactive portfolio management [6][19] - The company is positioned uniquely within the biopharmaceutical royalty financing sector, capitalizing on high demand for capital [9] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the royalty portfolio and the disciplined capital deployment approach, which positions the company for sustained long-term growth [11][33] - The company anticipates a strong pipeline of late-stage development programs and is optimistic about upcoming regulatory decisions and market expansions [33][27] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [17] - The company is actively engaged in monetizing older assets and exploring new investment opportunities across its portfolio [41][42] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and Lasofoxifene, with robust updates expected in the coming quarters [37] Question: Update on monetizing older assets - Management confirmed ongoing engagement with 5 to 10 opportunities for monetization and expects announcements by year-end [41] Question: Market opportunity for TZIELD - Management acknowledged the low royalty but emphasized the potential blockbuster opportunity with Sanofi's TZIELD, particularly in Stage 3 Type 1 diabetes [46] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS approval delay would have a negligible impact on the 2026 guidance, with a modest $4 million contribution assumed [51][63] Question: Differentiation of Castle Creek technology - Management discussed the potential advantages of the Castle Creek treatment over competitors, emphasizing its injectable nature and broader application [58]

Fourth Quarter and Full Year 2025 Financial Results F E B R U A R Y 2 6 , 2 0 2 6 | FINANCIAL | 48% Full-year royalty revenue growth over 2024 | | --- | --- | | Strong financial performance | 42% Full-year core adjusted EPS growth to $8.131 per share | | BUSINESS DEVELOPMENT | Scaling the BD function to capture value from our deep investment pipeline | | Highly productive, rigorous process | ~$1B Deployable capital (including credit facility) | | | Positions us for continued growth and expansion across our ...